A liquid biopsy is a principally non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring syndromes such as cancer. Liquid biopsy is the direct clinical application of two advances in the medical science, explicitly, human genome sequencing and increasing sensitivity of detecting approaches and assays. Liquid biopsy capitalizes on the qualitative and quantitative variance between dissimilar biomarkers such as cell-free DNA, circulating tumor cells (CTCs), cell-free RNA (cfRNA) fragments, methylated ctDNA, and miRNA in a patient’s blood. Although some of such fragments are released even throughout other situations such as trauma, there prevails a quantitative difference in the method of their composition and concentration as well as their degree of disintegration.
According to the report analysis, ‘Liquid Biopsy Market: Current Analysis and Forecast (2021-2027)’ states that the growth of the liquid biopsy market is principally driven by growing prevalence of cancer, increasing implementation of non-invasive diagnostic and monitoring approaches and growing preference of personalized medicines. In addition, technological improvements, increasing government initiatives to improve healthcare infrastructure and large availability funding’s for research and development for liquid biopsy is probable to underwrite to the growth of liquid biopsy market throughout the forecast duration.
Based on product and service, the liquid biopsy market is sectored into assay kits, instruments, and services. Among these, the assay kits segment is projected to be the fastest-increasing segment in the product and services market throughout the forecast period. Aspects such as the growing demand for liquid biopsy tests, augmenting the applications of liquid biopsies, and the requirement for reliable and precise assays are projected.
Based on end user, the liquid biopsy market is sectored into reference laboratories, hospitals and physician laboratories, academic and research centers. Reference laboratories form the greatest and fastest-increasing end-user sector of the liquid biopsy market. They can be accredited to the large volume of tests being outsourced to orientation laboratories from oncologists and hospitals.
Region wise, North America constitutes a foremost market for disposable medical device sensor and created revenue of USD XX million during 2020 due to the existence of well-established players in the region, emerging investment in healthcare R&D by players etc., However, the Asia Pacific region would augment at the greatest CAGR during the review period.
Additionally, companion diagnostics comprise tests or assays intended to help healthcare providers in making treatment decisions for patients rely on the best response to therapy. The co-development of companion diagnostics with therapeutic products can progressively alter the drug development procedure and commercialize drug candidates by yielding harmless drugs with improved therapeutic efficacy speedily and cost-effectively. With the augmented demand for high-priced specialist therapies and harmless drugs, the market for companion diagnostics has great growth potential. The increasing importance of companion diagnostics is also delivering the growth opportunities for the liquid biopsy market. Therefore, in the near years, it is predicted that the market of liquid biopsy will increase around the globe more actively over the near future.
For More Information, refer to below link:-
Follow Us:-
LinkedIn | Instagram | Facebook | Twitter | YouTube
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Support@kenresearch.com
+91-9015378249
